Acadia Pharma (NASDAQ: ACAD) reported Q1 EPS of ($0.44), $0.12 better than the analyst estimate of ($0.56). Revenue for the quarter came in at $48.9 million versus the consensus estimate of $47.06 million.

• ACADIA Reiterates 2018 Net Sales Guidance of $255 Million to $270 Million

For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.